Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines

被引:23
作者
Haag, Sebastian [1 ]
Andrews, Jane M. [2 ,3 ]
Katelaris, Peter H. [4 ]
Gapasin, Judith [5 ]
Galmiche, Jean Paul [6 ]
Hunt, Richard [7 ]
Layer, Peter [8 ]
Malfertheiner, Peter [9 ]
Holtmann, Gerald [10 ,11 ]
机构
[1] Univ Hosp Essen, Dept Gastroenterol & Hepatol, DE-45122 Essen, Germany
[2] Univ Adelaide, Dept Gastroenterol & Hepatol, Royal Adelaide Hosp, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Sydney, Concord Hosp, Dept Gastroenterol, Sydney, NSW 2006, Australia
[5] St Lukes Med Ctr, Inst Digest Dis, Quezon City, Philippines
[6] Univ Hosp, Hotel Dieu, Dept Gastroenterol & Hepatol, Nantes, France
[7] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Farncombe Family Digest Dis Res Inst, Hamilton, ON, Canada
[8] Israelit Krankenhaus, Dept Gastroenterol & Hepatol, Hamburg, Germany
[9] Univ Hosp Magdeburg, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany
[10] Univ Essen Gesamthsch, Execut Board, Essen, Germany
[11] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia
关键词
Proton pump inhibitors; Gastroesophageal reflux disease; Over-the-counter therapy; Histamine(2) receptor antagonist; GASTROESOPHAGEAL-REFLUX; BARRETTS-ESOPHAGUS; CONSENSUS CONFERENCE; ENDOSCOPIC FINDINGS; GENERAL-POPULATION; DISEASE; PREVALENCE; RISK; EPIDEMIOLOGY; IMPACT;
D O I
10.1159/000235953
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Symptoms of gastroesophageal reflux are widely prevalent. There is a continuum between subjects with mild reflux symptoms and those severely affected by gastroesophageal reflux disease (GERD). Both groups may at times access over-the-counter (OTC) therapies. For the purpose of this review, relevant papers, including national and international guidelines were reviewed and recommendations made for appropriate use of OTC proton pump inhibitor (PPI) therapy. Results: PPIs are the gold standard for treatment of reflux symptoms. OTC therapy with histamine 2 receptor antagonists (H2RAs) also plays a role. For the majority affected by reflux symptoms, effective symptom control is the most important outcome, as only a subgroup requires investigations or interventions. However, patients with alarm features (i.e. troublesome dysphagia, weight loss, predominant upper abdominal pain) are not recommended for OTC therapy and need prompt medical referral. Frequent relapses or failure to adequately respond to OTC therapy are additional triggers for medical assessment. Conclusions: OTC treatment of typical reflux symptoms (acid regurgitation, heartburn) with antacids and H2RAs is now accepted as safe and results in short-term relief of symptoms. There is no evidence of additional risk with OTC PPIs compared to these existing OTC therapies and PPIs are significantly more efficacious. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:226 / 234
页数:9
相关论文
共 55 条
  • [1] Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - Update 2004
    Armstrong, D
    Marshall, JK
    Chiba, N
    Enns, R
    Fallone, CA
    Fass, R
    Hollingworth, R
    Hunt, RH
    Kahrilas, PJ
    Mayrand, S
    Moayyedi, P
    Paterson, WG
    Sadowski, D
    van Zanten, SJV
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (01): : 15 - 35
  • [2] Peptic ulcer disease in a general adult population -: The Kalixanda study:: A random population-based study
    Aro, Pertti
    Storskrubb, Tom
    Ronkainen, Jukka
    Bolling-Sternevald, Elisabeth
    Engstrand, Lars
    Vieth, Michael
    Stolte, Manfred
    Talley, Nicholas J.
    Agreus, Lars
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (11) : 1025 - 1034
  • [3] Beck I T, 1997, Can J Gastroenterol, V11 Suppl B, p7B
  • [4] Prevalence of Barrett's esophagus in Hispanics is similar to Caucasians
    Bersentes, K
    Fass, R
    Padda, S
    Johnson, C
    Sampliner, RE
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (05) : 1038 - 1041
  • [5] Do gastrointestinal symptoms fluctuate in the short-term perspective?: The Kalixanda study
    Bolling-Sternevald, E.
    Aro, P.
    Ronkainen, J.
    Storskrubb, T.
    Talley, N. J.
    Junghard, O.
    Agreus, L.
    [J]. DIGESTIVE DISEASES, 2008, 26 (03) : 256 - 263
  • [6] Gastroesophageal reflux in the French general population:: national survey of 8000 adults
    Bretagne, JF
    Richard-Molard, B
    Honnorat, C
    Caekaert, A
    Barthélemy, P
    [J]. PRESSE MEDICALE, 2006, 35 (01): : 23 - 31
  • [7] Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials
    Caro, JJ
    Salas, M
    Ward, A
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (07) : 998 - 1017
  • [8] Chan M F, 1996, Gastrointest Endosc Clin N Am, V6, P287
  • [9] Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
    Chiba, N
    DeGara, CJ
    Wilkinson, JM
    Hunt, RH
    [J]. GASTROENTEROLOGY, 1997, 112 (06) : 1798 - 1810
  • [10] Epidemiology of gastrooesophageal reflux disease: A systematic review
    Dent, J
    El-Serag, HB
    Wallander, MA
    Johansson, S
    [J]. GUT, 2005, 54 (05) : 710 - 717